PROMOMED Ranked Among Russia’s Top Pharmaceutical Companies by Forbes

PROMOMED has strengthened its position among the top ten pharmaceutical companies in Russia, according to the results of 2024. The ranking was published in Forbes Healthcare and is based on data provided by the research agency AlphaRM.

PROMOMED’s strong performance in the ranking is driven by high sales growth dynamics and an impressive track record in clinical research — over 100 clinical trials conducted between 2022 and 2024. The company also leads the industry in the number of brands in its portfolio, with 350 registered medicinal products.

According to experts, this success was made possible by PROMOMED’s effective response to the challenges faced by the pharmaceutical industry in recent years. The COVID-19 pandemic and the withdrawal of foreign manufacturers from the Russian market accelerated the development of domestic pharmaceutical production, prompting an increase in both manufacturing capacity and the rapid development of local drugs and analogs of unavailable imported medicines. In 2022, Russian-made drugs accounted for 43% of pharmacy sales (in rubles); by 2024, this figure had risen to 47%

PROMOMED was one of the first companies to meet patient demand for semaglutide under the brand names Queensenta® and Welgia®, and introduced Tirzetta®, the country’s only tirzepatide-based product. The company also plans to expand its obesity treatment portfolio.

Forbes analysts highlight the continued growth in pharmaceutical sales and the increasing share of Russian-made medicines, suggesting that domestic manufacturers are actively investing in high-margin products, including original drug developments.

PROMOMED’s strategy remains focused on innovation — the key driver behind the company’s accelerated sales growth. In 2025, PROMOMED plans to launch eight innovative products from its core portfolio.